Effect of autotransfusion system on tumor recurrence and survival in hepatocellular carcinoma patients

Sami Akbulut, Cuneyt Kayaalp, Mehmet Yilmaz, Volkan Ince, Dincer Ozgor, Koray Karabulut, Cengiz Eris, Huseyin Ilksen Toprak, Cemalettin Aydin, Sezai Yilmaz

Sami Akbulut, Cuneyt Kayaalp, Mehmet Yilmaz, Volkan Ince, Dincer Ozgor, Koray Karabulut, Cengiz Eris, Cemalettin Aydin, Sezai Yilmaz, Division of Liver Transplantation Institute, Department of Surgery, Inonu University Faculty of Medicine, 44280 Malatya, Turkey

Huseyin Ilksen Toprak, Department of Anesthesiology, Inonu University Faculty of Medicine, 44280 Malatya, Turkey

Author contributions: Yilmaz S, Kayaalp C and Aydin C performed the surgical procedure; Akbulut S, Ozgor D, Ince V and Yilmaz M wrote the article and performed literature review, including a comprehensive literature search; Akbulut S, Eris C, Kayaalp C and Toprak HI designed the study and wrote the article; Toprak HI provided the CATS usage information; Karabulut K performed the statistical analysis.

Correspondence to: Sami Akbulut, MD, Division of Liver Transplantation Institute, Department of Surgery, Inonu University Faculty of Medicine, 44280 Malatya, Turkey. akbulutsami@gmail.com

Telephone: +90-422-3410660 Fax: +90-422-3410036 Received: October 27, 2012 Revised: December 25, 2012 Accepted: January 11, 2013 Published online: March 14, 2013

Abstract

AIM: To investigate the therapeutic efficacy and safety of continuous autotransfusion system (CATS) during liver transplantation of hepatocellular carcinoma patients.

METHODS: Eighty-three hepatocellular carcinoma (HCC) patients who underwent liver transplantation with intraoperative CATS (n = 24, CATS group) and without (n = 59, non-CATS group) between April 2006 and November 2011 at the Liver Transplant Institute of Inonu University were analyzed retrospectively. Postoperative HCC recurrence was monitored by measuring alpha-fetoprotein (AFP) levels at 3-mo intervals and performing imaging analysis by thoracoabdominal multidetector computed tomography at 6-month intervals. Inter-group differences in recurrence and correlations between demographic, clinical, and pathological data were assessed by ANOVA and χ² tests. Overall and disease-free survivals were calculated by the univariate Kaplan-Meier method.

RESULTS: Of the 83 liver transplanted HCC patients, 89.2% were male and the overall mean age was 51.3 ± 8.9 years (range: 18-69 years). The CATS and non-CATS groups showed no statistically significant differences in age, sex ratio, body mass index, underlying disease, donor type, graft-to-recipient weight ratio, Child-Pugh and Model for End-Stage Liver Disease scores, number of tumors, tumor size, AFP level, Milan and University of California San Francisco selection criteria, tumor differentiation, macrovascular invasion, median hospital stay, recurrence rate, recurrence site, or mortality rate. The mean follow-up time of the non-CATS group was 17.9 ± 12.8 mo, during which systemic metastasis and/or locoregional recurrence developed in 25.4% of the patients. The mean follow-up time for the CATS group was 25.8 ± 15.1 mo, during which systemic metastasis and/or locoregional recurrence was detected in 29.2% of the patients. There was no significant difference between the CATS and non-CATS groups in recurrence rate or site. Additionally, no significant differences existed between the groups in overall or disease-free survival.

CONCLUSION: CATS is a safe procedure and may decrease the risk of tumor recurrence in HCC patients.

© 2013 Baishideng. All rights reserved.

Key words: Liver transplantation; Hepatocellular carcinoma; Intraoperative blood salvage autotransfusion; Recurrence; Tumor cell dissemination

Akbulut S, Kayaalp C, Yilmaz M, Ince V, Ozgor D, Karabulut K, Eris C, Toprak HI, Aydin C, Yilmaz S. Effect of autotransfusion system on tumor recurrence and survival in hepatocellular carci-
noma patients. World J Gastroenterol 2013; 19(10): 1625-1631  Available from: URL: http://www.wjgnet.com/1007-9327/full/v19/i10/1625.htm DOI: http://dx.doi.org/10.3748/wjg.v19.i10.1625

INTRODUCTION

Since the first report of a successful human liver transplantation (LT) in 1963, this procedure has become the gold standard treatment for end-stage liver diseases, including acute liver failure, some metabolic liver diseases, primary liver cancers [such as hepatocellular carcinoma (HCC)], and some metastatic liver tumors[1-3]. Despite its widespread application, intraoperative hemorrhaging remains a significant limitation of the procedure[4]. The liver is directly connected to three different vascular systems, all of which may be weakened by the underlying disease’s pathogenic processes. Serious collateral circulation damage can accompany chronic liver disease and parallel severity of the disease status, increasing the risk of hemorrhage during LT surgery.

Clinical studies have identified the most important factors influencing development of major hemorrhage during surgery as adhesions between cirrhotic liver and surrounding structures, impaired clotting factor synthesis, inherent hemorrhage tendency of some liver diseases, retransplantation, portal vein thrombosis, and the experience level of the involved hepatobiliary surgical team[3-5,7]. Moreover, the extent of any hemorrhage that develops during surgery has been defined as one of the most significant factors affecting patient morbidity and mortality[6-8]. Suitable and balanced blood replacement is vital for patients undergoing major surgery. Unfortunately, the exogenous blood transfusion methods remain inadequate for resolving major blood loss that occurs during surgery. Various intraoperative blood salvage autotransfusion systems have been developed to overcome this clinical challenge, and are based upon re-use of the patient’s own blood that has accumulated at the surgical site[3,5,7].

Intraoperative blood salvage autotransfusion (IBSA) systems have emerged as cost-effective intraoperative tools that reduce the blood requirement by up to 60%[8]. However, some studies have indicated that the IBSA systems may cause cancer cell dissemination when used during cancer surgery[9], thereby increasing a patient’s risk for metastasis or recurrence. These results have not been upheld by other studies[10] and the therapeutic efficacy and safety of IBSA systems remain to be definitely established. The IBSA system employed in our healthcare institute is the continuous autotransfusion system (CATS) manufactured by Fresenius Kabi AG (Bad Homburg, Germany). To gain a better understanding of the therapeutic efficacy and safety of CATS during LT, this research study was designed to retrospectively analyze groups of HCC patients who underwent LT with and without CATS to determine postoperative rates of tumor recurrence and survival.

MATERIALS AND METHODS

Between April 2006 and November 2011, a total of 702 LTs were performed for 664 patients at the Liver Transplant Institute of Inonu University. Histopathological evaluation of the resected hepatectomy specimens revealed HCC foci of varying sizes and numbers for 17.1% (114/702) of the LT recipients. Of those, 28.1% (32/114) were considered ineligible for this study based upon insufficient follow-up data (< 3 mo; n = 2) and other-cause mortality within 3 mo after the LT (n = 29). From the remaining cohort of LT HCC patients, only those receiving primary liver transplants were selected for study inclusion. These 83 patients were then divided into two groups according to use of CATS during the LT surgery: CATS group, n = 24; non-CATS group, n = 59. The study participant selection process is outlined in Figure 1.

The following data were recorded for comparative analysis between the CATS and non-CATS groups: age, sex, body mass index (BMI; in kg/m²), underlying disease [hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection, or primary HCC], donor type (living/deceased), graft-to-reipient weight ratio (GRWR), Child–Pugh score, model for end-stage liver disease (MELD) score, number of tumors (< 10 or > 10), mean tumor size (in cm), Milan selection criteria (within/beyond), University of California San Francisco (UCSF) selection criteria (within/beyond), preoperative alpha-fetoprotein (AFP) levels (< 200 or > 200 ng/mL)[10], tumor differentiation (good/average/poor), macrovascular invasion (positive/negative), systemic metastasis and locoregional recurrence (positive/negative), recurrence site (hepatic and/or extrahepatic), current status (alive/died), and duration of follow-up (in mo).

The LT patients had been classified according to the Milan and UCSF criteria, both of which consider the diameter and number of HCC lesions observed by pathological examination to identify individuals likely to benefit from and survive the LT procedure. Specifically, patients with a single lesion of ≤ 5 cm diameter or with three or less lesions for which the largest was ≤ 3 cm were defined as ‘within’ Milan criteria, whereas patients with a single lesion of ≤ 6.5 cm or with three or less nodules for which the largest was ≤ 4.5 cm and the total tumor diameter was ≤ 8 cm were defined as ‘within’ UCSF criteria[6,10]. Donor type (deceased or living) was based on recommendations of the Milan group and the criteria accepted by the United Network of Organ Sharing. HCC cases within the Milan criteria (n = 30) were first given the chance of deceased-donor liver transplantation (DDLT; n = 3), whereas HCC cases beyond the Milan criteria were given living-donor liver transplantation (LDLT; n = 80).

In the DDLT procedure, venous drainage was facilitated by creating a wide-orifice venous drainage model using a saphenous vein graft followed by a wide-aperture anastomosis created between the wide-orifice hepatic vein and inferior vena cava. In the LDLT procedure, a hepato-caval anastomosis was created by using the standard piggyback technique. Anastomoses of other vascular
structures and the biliary tract were created by standard techniques.

In the early postoperative period, all known HCC cases were given the immunosuppressive regimen of low-dose sirolimus, steroids, and mycophenolate mofetil. The postoperative pharmaceutical regimen for non-HCC patients who received LT for end-stage liver disease included the calcineurin inhibitor; however, nine of those patients were subsequently diagnosed with HCC by pathology and were immediately switched to sirolimus treatment.

All patients were followed-up with measurement of AFP levels at 3-mo intervals and thoracoabdominal multidetector computed tomography (MDCT) imaging at 6-mo intervals. Suspcion of tumor recurrence led to shorter interval monitoring. Sixty-nine patients with chronic liver disease showed enhanced AFP values during follow-up and were monitored by dynamic MDCT. Five additional cases of primary HCC showed enhanced AFP levels by other tests carried out for symptoms unsolved by other tests.

RESULTS

Eighty-three HCC patients who underwent LT were analyzed. The male:female ratio was strongly biased (74:9). The mean age was 51.3 ± 8.9 years (range: 18-69). The CATS procedure was used in only 28.9% of the LT patients (CATS group, n = 4; non-CATS group, n = 59).

No significant differences were identified between the two groups in terms of age, sex, BMI, underlying disease, donor type, GRWR, Child-Pugh score, MELD score, tumor count, tumor size, AFP levels, Milan criteria, UCSF criteria, tumor differentiation, macrovascular invasion, presence of recurrence, recurrence site, mortality rate, or duration of hospital stay. Clinical and demographic data of both groups are shown in Table 1. The tumor characteristics of all patients are shown in Table 2. There was no difference between the groups for disease-free survival (Figure 2).

The mean follow-up time for the CATS group was 25.8 ± 15.1 mo (range: 4-53), during which systemic metastasis and/or locoregional recurrence was detected in 29.2% (7/24) of the patients. Four of these patients experienced locoregional recurrence with distant organ metastasis. One patient developed distant organ metastasis only, and the remaining two patients developed locoregional recurrence only. The mean follow-up time of the non-CATS group was 17.9 ± 12.8 mo (range: 4-56 mo), during which systemic metastasis and/or locoregional recurrence developed in 25.4% (15/59) of the patients. Ten patients experienced locoregional recurrence with distant organ metastasis. Two patients developed distant organ metastasis only, and the remaining three patients developed locoregional recurrence only. There was no significant difference between the CATS and non-CATS groups in recurrence rate (P < 0.7) or site (P < 0.8) (Table 2).

DISCUSSION

IBSA collects a patient's own blood accumulated at a
non-infectious complications associated with homologous blood transfusion occur less frequently with autologous blood transfusion\textsuperscript{[13,17]}. The autologous transfusion strategy boasts other advantages as well, including: lower volume requirement for exogenous blood, which increases cost-effectiveness; higher oxygen-carrying capacity, which accelerates wound healing; an immunostimulant effect, which reduces tumor recurrence and increases patient survival rates\textsuperscript{[17,19]}. Although positive results have been obtained with autologous transfusion in patients undergoing tumor surgery, the possibility that tumor dissemination may be caused by the IBSA transfusion method remains a significant concern\textsuperscript{[18,23,24]}. This potential risk was first reported by Yaw et al\textsuperscript{[13]}, who demonstrated the ability of tumor cells to pass through the filter of the Bentley autotransfusion device. Subsequently, the American Medical Association designated IBSA systems as unsuitable for use in cancer surgery\textsuperscript{[15,17]}. However, this restriction was later modified by the National Institute of Clinical Excellence, which indicated that IBSA systems could be used in cancer surgery when combined with leukocyte depletion filters (LDFs)\textsuperscript{[13,19]}. Since then, the Association of Anaesthetists of Great Britain and Ireland, Obstetric Anaesthetists Ax-

Table 1. Clinical and demographic characteristics of 83 hepatocellular carcinoma patients undergoing liver transplantation with and without continuous autotransfusion system (%)

| Patient Characteristics | CATS group (n = 24) | Non-CATS group (n = 59) | P  |
|-------------------------|---------------------|-------------------------|----|
| Sex                     |                     |                         |    |
| Male                    | 23 (95.8)           | 53 (88.1)               | 0.6|
| Female                  | 1 (4.2)             | 7 (11.9)                |    |
| Age, yr                 |                     |                         |    |
| mean ± SE               | 5.9 ± 1.2           | 5.0 ± 1.2               | 0.7|
| Median (range)          | 47 (38-68)          | 46 (18-69)              |    |
| BMI, kg/m\(^2\)        | 25.5 ± 0.8          | 25.1 ± 0.6              | 0.8|
| Underlying disease      |                     |                         |    |
| HBV                     | 18 (75)             | 39 (66)                 | 0.2|
| HBV + HCV               | 1 (4.2)             | 1 (1.7)                 |    |
| HBV + HDV               | 7 (29.2)            | 2 (3.4)                 |    |
| HCV                     | 0                   | 5 (8.5)                 |    |
| Primary HCC             | 0                   | 5 (8.5)                 |    |
| Wilson                  | 1 (4.2)             | 0                       |    |
| Donor type              |                     |                         |    |
| Living                  | 24 (100)            | 56 (95)                 | 0.1|
| Deceased                | 0                   | 3 (5)                   |    |
| GRWR                    | 1.10 ± 0.06         | 1.20 ± 0.05             | 0.9|
| Child score             |                     |                         |    |
| A                       | 6 (25.0)            | 18 (30.5)               | 0.7|
| B                       | 11 (45.8)           | 29 (49.2)               |    |
| C                       | 7 (29.2)            | 12 (20.3)               |    |
| MELD score              | 14.5 ± 0.9          | 13.6 ± 0.8              |    |
| Current status          |                     |                         |    |
| Alive                   | 13 (54.2)           | 41 (69.5)               | 0.2|
| Mortality               | 11 (45.8)           | 18 (30.5)               |    |
| Hospital stay, d (range)| 35.0 ± 13.8 (14-69) | 33.0 ± 38.2 (7-274)     | 0.6|
| Follow-up, mo (range)   | 25.8 ± 15.1 (4-53)  | 17.9 ± 12.8 (4-56)      |    |

HBV: Hepatitis B virus; HCV: Hepatitis C virus; CATS: Continuous autotransfusion system; BMI: Body mass index; HCC: Hepatocellular carcinoma; CATS: Continuous autotransfusion system; GRWR: Graft-to-recipient weight ratio; MELD: Model for End-Stage Liver Disease.

surgical site for re-use after aspiration, washing, filtration, and reinfusion\textsuperscript{[5,12-15,18]}. Following the first description of an IBSA system, the Bentley autotransfusion device, the Haemonetics Co. manufactured an IBSA-based device for washing and concentrating of erythrocytes; known as the Cell Saver (Haemonetics, Braintree, MA, United States), this system became commercially available in 1974. Nearly two decades later, the CATS was produced by the Fresenius Kabi Co. and has since been successfully applied in clinical practice.

Correlations of IBSA with postoperative complications, tumor recurrence, and mortality of patients receiving either homologous (allogenic) or autologous blood transfusion have been extensively studied, but the results have been inconsistent\textsuperscript{[8]}. Some studies have shown increased infection rates, delayed wound healing, and increased mortality, depending on the amount of blood used following homologous transfusion. Similarly, increased rates of tumor recurrence and mortality were reported for patients who underwent homologous transfusion. Further study has suggested this situation is associated with suppression of natural killer cells and cytotoxic T-cells, and activation of T-suppressor cells\textsuperscript{[13,16-18]}. Some studies have also demonstrated that the infectious and
Catling et al.\textsuperscript{[17]} showed that the Cell Saver filter failed to remove 91.2% of tumor cells but that integration of LDF resolved this completely. Another study of patients undergoing LT for HCC showed that the Cell Saver filter system alone removed only 25% of tumor cells, but 93.3% of tumor cells when integrated with an LDF\textsuperscript{[10]}. However, the IBSA CATS system used in our study was not integrated with LDF and was not associated with increased tumor recurrence. This difference may reflect the pore diameters of the different IBSA systems’ filters; for example, the pore diameter range of the Cell Saver’s filter is 20–150 µm, whereas the CATS machine’s filter is 40–120 µm. The different cancer cell types examined in the different studies may also influence the finding. Cervical cancer cells generally range from 25–65 µm diameter, whereas HCC cells range from 41–55 µm. Thus, certain cancers may require different filters and IBSA systems, integrated or unintegrated, should be applied accordingly.

Most studies of IBSA systems in gastrointestinal surgery have involved the liver and emergency situations\textsuperscript{[1,9,13,14,16,17,19-21]}. The complicated vascular structure of the liver and the frequency of severely cirrhotic conditions necessitate highly expert surgeons to lessen the high risk of hemorrhage. Nonetheless, massive blood loss remains a common occurrence in liver tumor surgeries involving major resection, and particularly in LT\textsuperscript{[7]}. Two studies have investigated the survival rates associated with IBSA systems in patients undergoing liver resection for HCC. Fujimoto et al.\textsuperscript{[23]} found equal cumulative overall and disease-free survival rates for patients treated with and without IBSA, and showed that the IBSA system was superior in its requirement for a lower volume of transfused blood. Hirano et al.\textsuperscript{[1]} reported better 10-year overall and disease-free survival rates for patients treated with IBSA. These authors also showed that the overall and disease-free survival rates were better for early-stage HCC cases treated with IBSA, but no significant advantage was found when used in advanced-stage HCC cases.

A few studies have reported on IBSA systems in LT. One study by Philips et al.\textsuperscript{[22]}, in which HCC and sepsis cases had been excluded, used of the Cell Saver during LT reduced the requirement for homologous blood transfusion and was cost-effective. Similarly, Sankarankuty et al.\textsuperscript{[12]} showed that use of the Cell Saver during LT reduced the requirement for homologous blood transfusion and lowered the risk of infection. In a study of CATS during LT performed by Massicote et al.\textsuperscript{[17]}, in which patients with preoperative infection had been excluded, the procedure reduced the requirement for homologous blood transfusion. Finally, Liang et al.\textsuperscript{[1]} showed that the Cell Saver integrated with LDF reduced bacterial contamination rates by 90.3%. Thus, IBSA systems exhibit a reduced requirement for homologous blood transfusion, are cost-effective, and have less risk of microbiological contamination.

According to our knowledge, only three studies have investigated the effect on tumor recurrence of IBSA systems used during LC in HCC patients\textsuperscript{[1,4,5]}. Folys et al.\textsuperscript{[8]}. reported use of the Cell Saver in 40 of 136 HCC patients.

The most comprehensive study of IBSA systems in cancer surgery was conducted as a meta-analysis of 10 published studies of 2326 prostate, liver, cervical, and gastrointestinal cancer patients\textsuperscript{[1,4,5,10,13,14,16,17,19-21]}. The results showed that IBSA did not constitute a risk in terms of tumor recurrence and metastasis. Yet, it has been shown in many studies that 91%-100% of tumor cells passing through the IBSA system filter reach the reinfusion bag\textsuperscript{[1,4,5,10,13,14,16,17,19-21]}, therefore, LDF should be integrated into the IBSA systems.

### Table 2. Detailed tumor characteristics of liver-transplanted hepatocellular carcinoma patients in the continuous autotransfusion system and non-continuous autotransfusion system groups (n, %)

| Tumor characteristics                  | CATS group (n = 24) | Non-CATS group (n = 59) | P value |
|----------------------------------------|---------------------|-------------------------|---------|
| **Tumor count**                        |                     |                         |         |
| < 10                                   | 17 (70.8)           | 47 (79.6)               | 0.4     |
| > 10                                   | 7 (29.2)            | 12 (20.3)               |         |
| **Mean tumor size, cm**                | 5.8 ± 0.9           | 5.2 ± 0.5               | 0.7     |
| **Milan criteria**                     |                     |                         |         |
| Within                                 | 8 (33.3)            | 22 (37.3)               | 0.7     |
| Beyond                                 | 16 (66.6)           | 37 (62.7)               |         |
| **UCSF criteria**                      |                     |                         |         |
| Within                                 | 9 (37.5)            | 29 (49.2)               | 0.3     |
| Beyond                                 | 15 (62.5)           | 30 (50.8)               |         |
| **AFP levels**                         |                     |                         |         |
| < 200                                  | 17 (70.8)           | 43 (73)                 | 0.7     |
| > 200                                  | 7 (29.2)            | 16 (27)                 |         |
| **Tumor differentiation**              |                     |                         |         |
| Good                                   | 12 (50.0)           | 24 (41.0)               | 0.6     |
| Average                                | 9 (37.5)            | 23 (39.0)               |         |
| Poor                                   | 3 (12.5)            | 20 (33.9)               |         |
| **Macrovascular invasion**             |                     |                         |         |
| Present                                | 2 (8.4)             | 3 (5.0)                 | 0.6     |
| Absent                                 | 22 (91.6)           | 56 (95.0)               |         |
| **HCC recurrence**                     |                     |                         |         |
| Present                                | 7 (29.2)            | 15 (25.4)               | 0.7     |
| Absent                                 | 17 (70.8)           | 44 (74.6)               |         |
| **Recurrence and/or metastasis**       |                     |                         |         |
| Hepatic                                | 2                    | 3                       | 0.8     |
| Extrahepatic                           | 1                    | 2                       |         |
| Both                                   | 4                    | 10                      |         |
| **Recurrence site**                    |                     |                         |         |
| Liver                                  | 2                    | 3                       |         |
| Lung                                   | 0                    | 2                       |         |
| Liver + bone                           | 1                    | 0                       |         |
| Liver + lung                           | 1                    | 1                       |         |
| Liver + stomach                        | 1                    | 0                       |         |
| Liver + bone + lung                    | 1                    | 0                       |         |
| Lung + suprarenal gland                | 1                    | 0                       |         |
| Liver + suprarenal gland               | 0                    | 4                       |         |
| Liver + suprarenal gland + lung        | 0                    | 2                       | 0       |
| Liver + esophagus                      | 0                    | 1                       |         |
| Liver + lung + brain                   | 0                    | 1                       |         |
| Liver + suprarenal gland + peritoneum  | 0                    | 1                       |         |

UCSF: University of California San Francisco; CATS: Continuous autotransfusion system; AFP: Alpha-fetoprotein; HCC: Hepatocellular carcinoma.
undergoing LT showed no influence on recurrence rate, overall survival, or disease-free survival during a mean follow-up period of 1015 d. In another study of the Cell Saver autotransfusion system in 31 of 47 HCC patients undergoing LT, Muscari et al.\(^3\) reported no influence on recurrence rates during a mean 34-month follow-up period. Liang et al.\(^3\) reported that 15 samples of blood collected in the re-infusion bag by the Cell Saver from the surgical sites of 20 HCC patients undergoing LT contained tumor cells; however, when a two-stage LDF system was used with the Cell Saver process, 14 of those samples were tumor-cell negative. In these studies, cases that were beyond the Milan and UCSF criteria and developed tumor perforation due to manipulation during surgery, the Cell Saver system was shown to be insufficient. It is, thus, presumed that the cell-holding capacity of the filters decreases due to the combined tumor load in the surgical area and that resulting from the IBSA device.

Studies in our laboratory have attempted to determine whether the IBSA system-displaced tumor cells enter systemic circulation and, if so, to what extent and whether their presence promotes metastasis. It is well established that the surgical procedure itself can pass tumor cells into the patient’s systemic circulation. However, once in circulation, these tumor cells have a 0.000 001%-0.01% chance of causing metastasis\(^{[0,17,19,20]}\). Therefore, cells passing into the circulation via the IBSA system are expected to have a less-than-absolute potential to cause metastases. In the current study, there was no difference in postoperative metastasis between the CATS group and the non-CATS group. This finding may reflect the fact that > 50% of the CATS group was beyond the Milan and UCSF criteria. Thus, our results indicate that cancer cells passing into the circulation did not cause metastasis.

This study has some important limitations that may have influenced the results. First, some patients’ records were missing blood transfusion data, making it impossible to determine how much CATS reduced the need for homologous blood transfusion. Second, the retrospective design of the study restricted the data available for analysis. A future study of prospective design may allow for quantitative detection of tumor cells or AFP using a genetic-based procedure, such as polymerase chain reaction; in this way, blood collected from surgical sites and in the re-infusion bag can be compared to a preoperative peripheral blood sample to more directly determine whether the CATS procedure contributed to recurrence, as opposed to preexisting tumor cells in circulation.

In conclusion, our findings suggest that the use of IBSA systems during LT of HCC patients has no effect on tumor recurrence and survival.

**REFERENCES**

1. Liang TB, Li DL, Liang L, Li JJ, Bai XL, Yu W, Wang WL, Shen Y, Zhang M, Zheng SS. Intraoperative blood salvage during liver transplantation in patients with hepatocellular carcinoma: efficiency of leukocyte depletion filters in the removal of tumor cells. *Transplantation* 2008; 85: 863-869 [PMID: 18360629]
2. Alqahtani SA. Update in liver transplantation. *Curr Opin Gastroenterol* 2012; 28: 230-238 [PMID: 22450898]
3. Liang TB, Li JJ, Li DL, Liang L, Bai XL, Zheng SS. Intraoperative blood salvage and leukocyte depletion during liver transplantation with bacterial contamination. *Clin Transplant* 2010; 24: 265-272 [PMID: 19788448]
4. Muscari F, Sue B, Vigouroux D, Duffas JP, Migueres I, Mathieu A, Lavayssiere L, Rostaing L, Fourtanier G. Blood salvage autotransfusion during transplantation for hepatocarcinoma: is there a risk of recurrence caused by intraoperative blood salvage autotransfusion? *Eur Surg Res* 2011; 47: 182-187 [PMID: 21986299 DOI: 10.1159/000330746]
5. Folts D, Zimmermann T, Heise M, Kaths M, Lautem A, Wiss G, Weiler N, Hoppe-Lotichius M, Hansen T, Otto G. Liver transplantation for hepatocarcinoma—is there a risk of recurrence caused by intraoperative blood salvage autotransfusion? *Transplant Int* 2005; 18: 1236-1239 [PMID: 16221153]
6. Hendriks HV, van der Meer J, Klompaker IJ, Choudhury N, Hageniers JA, Porte RJ, de Kam PJ, Slooff MJ, de Wolf JT. Blood loss in orthotopic liver transplantation: a retrospective analysis of transfusion requirements and the effects of autotransfusion of cell saver blood in 164 consecutive patients. *Blood Transfus* 2003; 11: Suppl 1: S87-S93 [PMID: 10850571]
7. Hirano T, Yamanaka J, Imuro Y, Fujimoto J. Long-term safety of autotransfusion during hepatectomy for hepatocellular carcinoma. *Surg Today* 2005; 35: 1042-1046 [PMID: 16341484 DOI: 10.1007/s00595-005-3082-8]
8. Sankarankutty AK, Teixeira AC, Souza FF, Mente ED, Oliveira GR, Almeida KC, Andrade CM, Origuella EA, Silva Ode C. Impact of blood salvage during liver transplanta-
tion on reduction in transfusion requirements. Acta Cir Bras 2006; 21 Suppl 1: 44-47 [PMID: 17013513 DOI: 10.1590/s0102-86502006000700011]

9 Gwak MS, Lee KW, Kim SY, Lee J, Joh JW, Kim SJ, Lee HH, Park JW, Kim CS, Lee SK. Can a leukocyte depletion filter (LDF) reduce the risk of reintroduction of hepatocellular carcinoma cells? Liver Transpl 2005; 11: 331-335 [PMID: 15719385 DOI: 10.1002/11.20346]

10 Sanai FM, Sobki S, Bzeizi KI, Shaikh SA, Alswat K, Al-Hamoudi W, Almadi M, Al Safi F, Abdo AA. Assessment of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma in Middle Eastern patients. Dig Dis Sci 2010; 55: 3568-3575 [PMID: 20397051 DOI: 10.1007/s10620-010-1201-x]

11 Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl 2002; 8: 765-774 [PMID: 12200775 DOI: 10.1053/jlts.2002.34892]

12 Waters JH, Yazer M, Chen YF, Kloke J. Blood salvage and cancer surgery: a meta-analysis of available studies. Transfusion 2012; 52: 2167-2173 [PMID: 22321196 DOI: 10.1111/j.1537-2995.2011.03555.x]

13 Ashworth A, Klein AA. Cell salvage as part of a blood conservation strategy in anaesthesia. Br J Anaesth 2010; 105: 401-416 [PMID: 20802228 DOI: 10.1093/bja/aep244]

14 Raval JS, Nelson JB, Woldemichael E, Triulzi DJ. Intraoperative cell salvage in radical prostatectomy does not appear to increase long-term biochemical recurrence, metastases, or mortality. Transfusion 2012; 52: 2590-2593 [PMID: 22612861 DOI: 10.1111/j.1537-2995.2012.03682.x]

15 Dionigi G, Boni L, Rovera F, Rausei S, Cuffari S, Cantone G, Bacuzzi A, Dionigi R. Effect of perioperative blood transfusion on clinical outcomes in hepatic surgery for cancer. World J Gastroenterol 2009; 15: 3976-3983 [PMID: 19705491 DOI: 10.3748/wjg.v15.i26.3976]

16 Engle DB, Connor JP, Morris PC, Bender DP, De Geest K, Ahmed A, Goodheart MJ. Intraoperative autologous blood transfusion use during radical hysterecomy for cervical cancer: long-term follow-up of a prospective trial. Arch Gynecol Obstet 2012; 286: 717-721 [PMID: 22569711 DOI: 10.1007/s00404-012-2351-1]

17 Catling S, Williams S, Freites O, Rees M, Davies C, Hopkins L. Use of a leukocyte filter to remove tumour cells from intraoperative cell salvage blood. Anaesthesia 2008; 63: 1338-1339 [PMID: 19032302 DOI: 10.1111/j.1365-2044.2008.05637.x]

18 Takemura M, Osugi H, Higashino M, Takada N, Lee S, Kinoshita H. Effect of substituting allogenic blood transfusion with autologous blood transfusion on outcomes after radical oesophagectomy for cancer. Ann Thorac Cardiovasc Surg 2005; 11: 293-300 [PMID: 16299455]

19 Esper SA, Waters JH. Intra-operative cell salvage: a fresh look at the indications and contraindications. Blood Transfus 2011; 9: 139-147 [PMID: 21251468 DOI: 10.2450/2011.0081-10]

20 Ubee S, Kumar M, Athmanathan N, Singh G, Vesey S. Intraoperative red blood cell salvage and autologous transfusion during open radical retropubic prostatectomy: a cost-benefit analysis. Ann R Coll Surg Engl 2011; 93: 157-161 [PMID: 22041147 DOI: 10.1080/003588411X561044]

21 Gorin MA, Eldfrawy A, Manoharan M, Soloway MS. Oncologic outcomes following radical prostatectomy with intraoperative cell salvage. World J Urol 2012; 30: 379-383 [PMID: 21847657 DOI: 10.1007/s00345-011-0746-4]

22 Fujimoto J, Okamoto E, Yamanaka N, Oriyama T, Furukawa K, Kawamura E, Tanaka T, Tomoda F. Efficacy of autotransfusion in intraoperative cell salvage. Br J Anaesth 2011; 105: 139-147 [PMID: 22321196 DOI: 10.1111/j.1537-2995.2011.03555.x]

23 Phillips SD, Maguire D, Deshpande R, Muiesan P, Bowles MJ, Rela M, Heaton ND. A prospective study investigating the cost effectiveness of intraoperative blood salvage during liver transplantation. Transplantation 2006; 81: 536-540 [PMID: 16495800 DOI: 10.1097/01.tp.0000199318.17013.c5]

24 Massicotte I, Thibault L, Beauleau D, Roy JD, Roy A. Evaluation of cell salvage autotransfusion utility during liver transplantation. HPB (Oxford) 2007; 9: 52-57 [PMID: 18333113 DOI: 10.1016/j.hpb.2006.09.005]